Lupin Limited announced that it has partnered with Laboratorios ERN for the launch of Lupin’s Luforbec beclometasone / formoterol MDI for the treatment of asthma and COPD in Spain. Luforbec, a generic version of Chiesi’s Fostair / Foster MDI, was launched in the UK in 2021 and in Germany in 2023.
Lupin President EMEA and Emerging Markets Thierry Volle commented, “The launch of Luforbec in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care. Together, we are building something truly exciting for patients and healthcare professionals,”
Laboratorios ERN CEO David Solanes said, “Partnering with Lupin allows us to bring a proven, high-value respiratory therapy to Spanish patients and healthcare professionals. It represents an opportunity for ERN to expand into a new therapeutic area.”
Read the Lupin press release
